Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tividenofusp alfa versus idursulfase in pediatric and young adult MPS II
2024-510990-21-00Phase 3Authorised
- Sponsor
- Denali Therapeutics Inc.
- Start
- Nov 2022
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in mucopolysaccharidosis type 2 comparing Tividenofusp alfa with Idursulfase control (2 arms). Planned start Nov 2022; status: authorised.
02
Drugs
tividenofusp alfaidursulfase
03
Conditions
mucopolysaccharidosis type 2
Beyond the preview
Go deeper on 2024-510990-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510990-21-00.